6 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
-2024, reflecting PanCAN's updated timing to complete database lock and subsequent analysis of the topline results by the independent Statistical
atd9za6e8dcgpamemrjc5 w7q
ABAT
ABIO
ACORQ
3 Apr 24
. (NASDAQ:TCON) dipped 24.2% to $0.3148 as the company issued an update on ongoing ENVASARC Phase 2 pivotal trial following Independent Data Monitoring
- Prev
- 1
- Next